While the use of MEK inhibition in glioblastoma therapy is a relatively new topic in pharmacotherapy, there have been numerous studies in the pre-clinical setting examining the application of these agents on glioblastoma cell lines (Table 1). The gene discussed is MAP2K7; the disease is glioblastoma.